SavedAdd your journal

Journals / European Journal of Rheumatology / 2016 / Cilt: 3 - Sayı: 2

The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus

Doruk ERKAN
Ozan ÜNLÜ
Stephane ZUİLY
Pages
75–84
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Until further studies are available, physicians should discuss the risk/benefits of LDA or anticoagulation as well as the available literature with patients

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Antiphospholipid syndrome (APS) is the association of thrombosis and/or pregnancy morbidity with antiphospholipid antibodies (aPL).
📊
Key Findings & Data:Compared with SLE patients without aPL, those with aPL have a higher prevalence of thrombosis, pregnancy morbidity, valve disease, pulmonary hypertension, livedo reticularis, thrombocytopenia, hemolytic anemia, acute/chronic renal vascular lesions, and moderate/severe cognitive impairment; worse quality of life; and higher risk of organ damage.
💡
Conclusion & Impact:Until further studies are available, physicians should discuss the risk/benefits of LDA or anticoagulation as well as the available literature with patients
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Antiphospholipid syndrome (APS) is the association of thrombosis and/or pregnancy morbidity with antiphospholipid antibodies (aPL). Thirty to forty percent of systemic lupus erythematosus (SLE) patients are tested positive for aPL, which may have an impact on the SLE presentation, management, and prognosis. Compared with SLE patients without aPL, those with aPL have a higher prevalence of thrombosis, pregnancy morbidity, valve disease, pulmonary hypertension, livedo reticularis, thrombocytopenia, hemolytic anemia, acute/chronic renal vascular lesions, and moderate/severe cognitive impairment; worse quality of life; and higher risk of organ damage. The use of low-dose aspirin (LDA) is controversial for primary thrombosis and pregnancy morbidity prevention because of the lack of strong prospective controlled data. Similarly, the use of anticoagulation is controversial for patients with an aPL-related nephropathy. Until further studies are available, physicians should discuss the risk/benefits of LDA or anticoagulation as well as the available literature with patients

🔖

Cite This Article

ERKAN, D., ÜNLÜ, O., ZUİLY, S. (2022). The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. European Journal of Rheumatology, Cilt: 3 - Sayı: 2, 75–84. https://ajindex.com/articles/511782

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consen- sus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306. [CrossRef] Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD. Manifestations of Systemic Lupus Erythemato- sus. Maedica 2011; 6: 330-6.
  2. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifes- tations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019-27. [CrossRef] Chambers SA, Allen E, Rahman A, Isenberg D. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford) 2009; 48: 673-5. [CrossRef] Erkan D, Yazici Y, Sobel R, Lockshin MD. Pri- mary antiphospholipid syndrome: functional outcome after 10 years. J Rheumatol 2000; 27: Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 2000; 15: 145-51.[CrossRef] Merrill JT, Buyon JP, Utset T. A 2014 update on the management of patients with systemic lupus erythematosus. Semin Arthritis Rheum 2014; 44: e1-2. [CrossRef] Reynaud Q, Lega J-C, Mismetti P, Chapelle C, Wahl D, Cathébras P, et al. Risk of venous and arterial thrombosis according to type of an- tiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic re- view and meta-analysis. Autoimmun Rev 2014; 13: 595-608. [CrossRef] Borowoy AM, Pope JE, Silverman E, Fortin PR, Pineau C, Smith CD, et al. Neuropsychiatric lu- pus: the prevalence and autoantibody associ- ations depend on the definition: results from the 1000 faces of lupus cohort. Semin Arthritis Rheum 2012; 42: 179-85. [CrossRef] Gustafsson JT, Gunnarsson I, Kallberg H, Pet- tersson S, Zickert A, Vikerfors A, et al. Cigarette smoking, antiphospholipid antibodies and vas- cular events in Systemic Lupus Erythematosus. Ann Rheum Dis 2015; 74: 1537-43. [CrossRef] Taraborelli M, Leuenberger L, Zhang W, Tincani A, Salmon J, Erkan D. The Effect of Clinically Sig- nificant Antiphospholipid Antibody Positivity on Organ Damage in Systemic Lupus Erythe- matosus. Arthritis Rheum 2014; 66: 8-9.
  3. Vila P, Hernandez M, Lopez-Fernandez M, Batlle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 1994; 72: 209-13.
  4. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anti- coagula